Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, discusses improvements in lung function observed in patients enrolled in the BOREAS trial. The results of the BOREAS ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. At 52 weeks, patients receiving dupilumab vs. placebo ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. At 52 weeks, patients receiving dupilumab vs. placebo ...

Dupilumab significantly reduced exacerbations and improved lung function in adults with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation, based on data from more than ...

Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, shares the latest clinical discoveries from the BOREAS trial on type 2 inflammation in patients with chronic ...

Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -- dupilumab -- that showed rapid and sustained improvements in patients in a pivotal Phase 3 ...

High airway TSLP asthma is linked to severe disease, type 2 inflammation, and airway remodelling. Learn more about how TSLP may guide targeted treatment.

Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug - dupilumab - that showed rapid and sustained improvements in patients in a pivotal Phase 3 ...

Bhatt’s study, "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was recently published in The New England Journal of Medicine. Bhatt and colleagues conducted a multicenter ...

A rare cell type in the lungs is essential to survival from the COVID-19 virus, a new study shows. Experiments in mice infected with the SARS-CoV-2 virus revealed that the immune cell class in ...